Natalie S Grover1, Barbara Savoldo2. 1. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27516, USA. 2. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27516, USA. bsavoldo@med.unc.edu.
Abstract
PURPOSE OF REVIEW: This review discusses novel immunotherapeutic approaches to treat Hodgkin lymphoma (HL), specifically PD-1 inhibitors and cellular immunotherapy. RECENT FINDINGS: PD-1 inhibitors have shown promising results in the treatment of relapsed or refractory HL, leading to FDA approval of nivolumab and pembrolizumab, although complete remissions are rare. Chimeric antigen receptor T cells directed against CD30 have been investigated with preliminary clinical trials showing minimal toxicities and some responses in heavily pre-treated patients with HL. HL is unique as it consists of a small percentage of malignant cells (Hodgkin Reed Sternberg cells) surrounded by an inflammatory microenvironment which promotes tumor growth and suppresses immune responses, making it an ideal target for immunotherapeutic approaches, such as PD-1 inhibitors and cellular immunotherapy. Current research is focused on overcoming barriers to efficacy via rational combinations that overcome resistance to therapy.
PURPOSE OF REVIEW: This review discusses novel immunotherapeutic approaches to treat Hodgkin lymphoma (HL), specifically PD-1 inhibitors and cellular immunotherapy. RECENT FINDINGS: PD-1 inhibitors have shown promising results in the treatment of relapsed or refractory HL, leading to FDA approval of nivolumab and pembrolizumab, although complete remissions are rare. Chimeric antigen receptor T cells directed against CD30 have been investigated with preliminary clinical trials showing minimal toxicities and some responses in heavily pre-treated patients with HL. HL is unique as it consists of a small percentage of malignant cells (Hodgkin Reed Sternberg cells) surrounded by an inflammatory microenvironment which promotes tumor growth and suppresses immune responses, making it an ideal target for immunotherapeutic approaches, such as PD-1 inhibitors and cellular immunotherapy. Current research is focused on overcoming barriers to efficacy via rational combinations that overcome resistance to therapy.
Authors: Margaretha G M Roemer; Ranjana H Advani; Robert A Redd; Geraldine S Pinkus; Yasodha Natkunam; Azra H Ligon; Courtney F Connelly; Christine J Pak; Christopher D Carey; Sarah E Daadi; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Margaret A Shipp; Scott J Rodig Journal: Cancer Immunol Res Date: 2016-10-13 Impact factor: 11.151
Authors: Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp Journal: Blood Date: 2010-07-13 Impact factor: 22.113
Authors: Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer Journal: N Engl J Med Date: 2016-07-14 Impact factor: 91.245
Authors: Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert Journal: Lancet Oncol Date: 2016-07-20 Impact factor: 41.316
Authors: Sakthi Rajendran; Yating Li; Evelyn Ngoh; Hiu Yi Wong; Man Si Cheng; Cheng-I Wang; Herbert Schwarz Journal: Front Oncol Date: 2019-09-24 Impact factor: 6.244